Emerging Markets Earnings Roundup: Amgen, Sanofi (Part 14)
This article was originally published in PharmAsia News
Executive Summary
Amgen is fairly quiet on international in the second quarter, but Sanofi says it is back on track in Brazil and emerging markets generally.
You may also be interested in...
High Valuations Sideline Sanofi From The M&A Game…For Now
Sanofi CEO Chris Viehbacher said the company is focusing mainly on bolt-on acquisitions because valuations for targets have ballooned so significantly. Inversion deals are further inflating assets, he said.
Amgen Cuts Costs And Jobs, Despite Strong Quarter
The big biotech is restructuring as some of its more successful products could face generic competition; cuts will be company-wide, but focused in the U.S.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.